Assembly Biosciences reports interim Phase 1a data from clinical study of oral entry inhibitor candidate ABI-6250 for hepatitis delta virus (HDV)
– Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement
– Further pharmacological assessment to be conducted in parallel with Phase 2 preparation
Assembly Biosciences reports positive interim results from Phase 1b clinical study of long-acting helicase-primase inhibitor candidate ABI-5366 showing reductions in viral shedding rate and genital lesion rate in recurrent genital herpes
– 94% reduction in herpes simplex virus type 2 (HSV-2) shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period
– 94% reduction in genital lesion rate, also statistically significant, observed with 350 mg weekly oral dose compared to placebo over same period
– Favorable safety and tolerability profile observed in the first two cohorts evaluating weekly oral doses of ABI-5366
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.